The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma
Clinical trial NCT07073833 · RECRUITING
Trial details
- NCT number
- NCT07073833
- Sponsor
- Imbioray (Hangzhou) Biomedicine Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-01
- Primary completion
- 2027-07-30
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.